German discount reveal has drugmakers worried; Novo Nordisk teams up with NHS on diabetes; Shire looks to expand Elvanse;

> Germany's proposal to reveal drug discounts has Big Pharma worried that other countries will press for similarly low prices. Report

> Novo Nordisk ($NVO) teamed up with National Health Service primary care trusts on a diabetes-care program. Report

> Shire ($SHPG) filed its ADHD drug Elvanse for approval in the U.K., Denmark and Sweden; it's sold as Vyvanse in the U.S. Release

> Drug companies are increasing their use of key account managers to deal with payers and formulary decision-makers, but sales reps are still a necessary part of pharma marketing strategies. Report

> Ranbaxy Laboratories and Teva Pharmaceutical Industries ($TEVA) agreed to settle collusion claims with the New York Attorney General, in a probe of their generic Lipitor sales tactics. Report

And Finally... Apple ($AAPL) is looking to take a bite of the medical devices market. Report

Suggested Articles

Pfizer and Astellas are chasing a new nod for prostate cancer drug Xtandi, and thanks to the FDA, they might not have to wait that long.

As AZ and FibroGen have yet to submit the novel anemia drug to the U.S. regulators, national reimbursement talks are already underway in China.

Health and Human Services, hoping to resurrect a rule that would force drug prices into TV ads, appealed a judge's decision that blocked it.